Enorama Pharma AB OMXSTO:ERMA:
POSTPONES PUBLICATION OF ITS 2025 YEAR-END REPORT
Enorama Pharma Postpones Its 2025 Year-End Report
Earlier from Enorama Pharma
- Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision
- Bulletin from the extraordinary general meeting in Enorama Pharma AB (publ)
- Enorama Pharma Q3 Operating Loss Widens To SEK 12.3 Mln
- Enorama Pharma CEO Daniel Schröder Resigns
- ERMA: Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus
Later from Enorama Pharma
- Enorama Pharma Enters Loan Agreement With DS Global
- Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting
- Enorama Pharma Postpones Publication Of 2025 Report Due To Control Balance Sheet
- Balance Sheet For Liquidation Purposes Shows Enorama Pharma Equity Is Less Than Half Of Registered Share Capital
- Enorama Pharma Reports Q4 Net Sales Of SEK 1.75 Million
Follow Enorama Pharma into a list and get an email when it puts out news.
Follow Enorama Pharma